Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dan ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Feb 25, 2021 4:34pm
190 Views
Post# 32663863

RE:RE:Dan ...

RE:RE:Dan ...
Layth1990 wrote:

Everyone is upset because what happened killed the nuance rally. Ofcourse there is more into the story than this. I'm sure the managment will kill the sp more once they announce IP deal with the holding. Things could be excuted in a better way. 

basically anyone who boughy at the latest offering or during the nuance deal are down at least 25%. Those are new investors and managment just slashed them. 



And all will pass - sitting in the best financial position ever - lots of potential.  The sadness will eventually evaporate.  IMO.

-----

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antibe Therapeutics (ATBPF) and United Therapeutics (UTHR) with bullish sentiments.

Antibe Therapeutics (ATBPF)

In a report released today, Tania Gonsalves from Canaccord Genuity maintained a Buy rating on Antibe Therapeutics, with a price target of C$14.50. The company’s shares closed last Wednesday at $4.34.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities